AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8875683 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (15 mg/kg)
Number of subjects: 94
Study 1999935 — intervention group
Group type: EXPERIMENTAL
Intervention: International normalized ratio of 2.0 to 2.99 (Group A)
Number of subjects: 99
Study 1999935 — intervention group
Group type: COMPARATOR
Intervention: International normalized ratio of 3.0 to 4.5 (Group B)
Number of subjects: 99
Study 6203596 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dextran 70 and dihydroergotamine (DHE)
Number of subjects: 259
Study 6203596 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70 alone
Number of subjects: 259
Study 31579904 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin 10 or 25 mg
Number of subjects: 0
Study 31579904 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 29958127 — intervention group
Group type: EXPERIMENTAL
Intervention: iTAB (individualized texting for adherence building); n=50
Number of subjects: 75
Study 29958127 — intervention group
Group type: COMPARATOR
Intervention: Active control; n=25
Number of subjects: 75
Study 26993374 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat phantom model
Number of subjects: 0
Study 26993374 — intervention group
Group type: COMPARATOR
Intervention: Fresh-frozen human cadaver
Number of subjects: 0
Study 26993374 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and deliberate feedback
Number of subjects: 0
Study 24646104 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg sc every 6 months (n = 500)
Number of subjects: 1262
Study 24646104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 511)
Number of subjects: 1262
Study 24646104 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alendronate 35 mg weekly (n = 251)
Number of subjects: 1262
Study 22450015 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block with ropivacaine (0.5% combined with epinephrine)
Number of subjects: 50
Study 22450015 — intervention group
Group type: COMPARATOR
Intervention: Control group (without intercostal nerve block)
Number of subjects: 50
Study 20222915 — intervention group
Group type: EXPERIMENTAL
Intervention: lesogaberan (0.8 mg/kg)
Number of subjects: 24
Study 20222915 — intervention group
Group type: EXPERIMENTAL
Intervention: baclofen (40 mg)
Number of subjects: 24
Study 20222915 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 18019850 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐threo‐methylphenidate (d‐MPH) 5‐15 mg twice daily
Number of subjects: 66
Study 18019850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 15692131 — intervention group
Group type: EXPERIMENTAL
Intervention: Reclining hospital chair
Number of subjects: 132
Study 15692131 — intervention group
Group type: COMPARATOR
Intervention: Gurney
Number of subjects: 132
Study 11991884 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative expiratory pressure (NEP) of -10 cm H2O
Number of subjects: 6
Study 11991884 — intervention group
Group type: COMPARATOR
Intervention: No negative expiratory pressure (baseline)
Number of subjects: 6
Study 9505155 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g SPP
Number of subjects: 7
Study 9505155 — intervention group
Group type: COMPARATOR
Intervention: 20 g SPP (raw)
Number of subjects: 7
Study 9505155 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g SPP (baked into bread)
Number of subjects: 7
Study 9505155 — intervention group
Group type: COMPARATOR
Intervention: 20 g lactulose
Number of subjects: 7
Study 9505155 — intervention group
Group type: COMPARATOR
Intervention: 20 g oat bran
Number of subjects: 7
Study 9505155 — intervention group
Group type: COMPARATOR
Intervention: 20 g wheat bran
Number of subjects: 7
Study 9505155 — intervention group
Group type: COMPARATOR
Intervention: 180 g wheat flour (control bread)
Number of subjects: 7
Study 9505155 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 g wheat flour with 20 g raw SPP (bread)
Number of subjects: 7
Study 9505155 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 g wheat flour with 20 g SPP (baked bread)
Number of subjects: 7
Study 8546510 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms/day
Number of subjects: 13
Study 8546510 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 800 micrograms/day
Number of subjects: 13
Study 2507265 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin plus 10 mg glyburide
Number of subjects: 20
Study 2507265 — intervention group
Group type: COMPARATOR
Intervention: Insulin plus placebo
Number of subjects: 20
Study 799563 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol alone (10 mg)
Number of subjects: 54
Study 799563 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + amiloride (25 mg + 2-5 mg)
Number of subjects: 54
Study 799563 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol + hydrochlorothiazide + amiloride (10 mg + 25 mg + 2-5 mg)
Number of subjects: 54
Study 799563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 30503844 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 7787
Study 30503844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 7787
Study 30503844 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day readmission
Number of subjects: 7787
Study 30503844 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe acute pancreatitis (SAP)
Number of subjects: 7787
Study 30503844 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend admission
Number of subjects: 7787
Study 30503844 — intervention group
Group type: EXPERIMENTAL
Intervention: >1 week of hospitalization
Number of subjects: 7787
Study 30503844 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCP
Number of subjects: 7787
Study 28632204 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention (BI)
Number of subjects: 15
Study 28632204 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention plus d‐cycloserine (BI+DCS)
Number of subjects: 15
Study 28632204 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 15
Study 25713096 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid format (online delivery)
Number of subjects: 0
Study 25713096 — intervention group
Group type: COMPARATOR
Intervention: Traditional format (in-person delivery)
Number of subjects: 0
Study 23391728 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised intervention for depression and COPD (PID‐C)
Number of subjects: 138
Study 23391728 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 138
Study 21054800 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical misoprostol (100 µg)
Number of subjects: 17
Study 21054800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 17853018 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral periprostatic infiltration of 5 cm(3) of 2% lidocaine
Number of subjects: 160
Study 17853018 — intervention group
Group type: COMPARATOR
Intervention: Bilateral periprostatic infiltration of 5 cm(3) of 0.9% saline solution
Number of subjects: 160
Study 15913843 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline acetyltransferase (ChAT) activity in PDD cases
Number of subjects: 39
Study 15913843 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline acetyltransferase (ChAT) activity in DLB + P cases
Number of subjects: 39
Study 15913843 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 39
Study 15913843 — intervention group
Group type: COMPARATOR
Intervention: DLB - P
Number of subjects: 39
Study 15913843 — intervention group
Group type: COMPARATOR
Intervention: PD
Number of subjects: 39
Study 15493518 — intervention group
Group type: EXPERIMENTAL
Intervention: Patella taping combined with a standardized exercise program
Number of subjects: 30
Study 15493518 — intervention group
Group type: COMPARATOR
Intervention: Placebo patella taping and exercise program
Number of subjects: 30
Study 15493518 — intervention group
Group type: COMPARATOR
Intervention: Exercise program alone
Number of subjects: 30
Study 11309457 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stroke unit
Number of subjects: 121
Study 11309457 — intervention group
Group type: COMPARATOR
Intervention: General medical wards
Number of subjects: 121
Study 9116938 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic
Number of subjects: 38
Study 9116938 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein
Number of subjects: 38
Study 7840587 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 3000
Study 7840587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000
Study 2896828 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (E-Z) measles vaccine, 40,000 plaque forming units
Number of subjects: 74
Study 2896828 — intervention group
Group type: COMPARATOR
Intervention: Schwarz vaccine, 40,000 plaque forming units
Number of subjects: 74
Study 30431581 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaolin-filled pad (QuikClot)
Number of subjects: 260
Study 30431581 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemostasis
Number of subjects: 260
Study 28402415 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose misoprostol (800 μg vaginally on Day 1)
Number of subjects: 160
Study 28402415 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat-dose misoprostol (800 μg vaginally on Day 1, with a second dose if required on Day 4)
Number of subjects: 160
Study 28402415 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat-dose misoprostol
Number of subjects: 160
Study 28402415 — intervention group
Group type: COMPARATOR
Intervention: Single-dose misoprostol
Number of subjects: 160
Study 26185033 — intervention group
Group type: EXPERIMENTAL
Intervention: BMP-2/H (1 mg/mL of rhBMP-2 soaked with hydroxyapatite granules, 0.5 to 2.0 g; n = 65)
Number of subjects: 127
Study 26185033 — intervention group
Group type: COMPARATOR
Intervention: ABX (inorganic bovine bone xenograft, 0.5 to 2.0 g; n = 62)
Number of subjects: 127
Study 23295964 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and hepatitis B vaccine (first dose)
Number of subjects: 283
Study 23295964 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and hepatitis B vaccine (third dose)
Number of subjects: 283
Study 23295964 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and hepatitis B vaccine (first booster dose)
Number of subjects: 283
Study 21365662 — intervention group
Group type: EXPERIMENTAL
Intervention: GSM 900
Number of subjects: 30
Study 21365662 — intervention group
Group type: EXPERIMENTAL
Intervention: WCDMA
Number of subjects: 30
Study 21365662 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 30
Study 21365662 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-of-day effects
Number of subjects: 30
Study 18480196 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 2331
Study 18480196 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid
Number of subjects: 2331
Study 18480196 — intervention group
Group type: COMPARATOR
Intervention: Aminocaproic acid
Number of subjects: 2331
Study 16568143 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 Hz cutaneous electrical stimulation in patients with SCI
Number of subjects: 75
Study 16568143 — intervention group
Group type: COMPARATOR
Intervention: 3 Hz cutaneous electrical stimulation in control subjects
Number of subjects: 75
Study 14658976 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone (25 mg, 50 mg, or 75 mg every 2 weeks for 12 months)
Number of subjects: 615
Study 14658976 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone
Number of subjects: 615
Study 10623910 — intervention group
Group type: EXPERIMENTAL
Intervention: PWP-GT model
Number of subjects: 0
Study 10623910 — intervention group
Group type: EXPERIMENTAL
Intervention: TT-R model
Number of subjects: 0
Study 10623910 — intervention group
Group type: EXPERIMENTAL
Intervention: WLW model
Number of subjects: 0
Study 10623910 — intervention group
Group type: EXPERIMENTAL
Intervention: LWA model
Number of subjects: 0
Study 9179067 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonabsorbable antibiotic lozenge
Number of subjects: 112
Study 9179067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 8482427 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple logistic regression models
Number of subjects: 1485
Study 8482427 — intervention group
Group type: COMPARATOR
Intervention: Impaired glucose tolerance
Number of subjects: 1485
Study 2869679 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol 50 mg
Number of subjects: 13
Study 2869679 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol 200 mg
Number of subjects: 13
Study 2869679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 29469926 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation throughout pregnancy
Number of subjects: 39
Study 29469926 — intervention group
Group type: COMPARATOR
Intervention: Folic acid supplementation during the first trimester
Number of subjects: 39
Study 27612561 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity (HI) exercise program
Number of subjects: 0
Study 27612561 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-to-Moderate Intensity (LMI) exercise program
Number of subjects: 0
Study 26509172 — intervention group
Group type: EXPERIMENTAL
Intervention: Media campaign and clinic intervention focused on CRC screening
Number of subjects: 1123
Study 26509172 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 1123
Study 24307876 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise during hemodialysis for 16 weeks
Number of subjects: 26
Study 24307876 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 26
Study 24307876 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 26
Study 19557424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail therapy (ESWT, HBO, alendronate)
Number of subjects: 63
Study 19557424 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave treatment (ESWT) alone
Number of subjects: 63
Study 17974698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell infusion
Number of subjects: 40
Study 17974698 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 16042638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement and behavioral therapies
Number of subjects: 0
Study 16042638 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory smoking
Number of subjects: 0
Study 16042638 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous reduction
Number of subjects: 0
Study 16042638 — intervention group
Group type: COMPARATOR
Intervention: Relapse after trying to quit
Number of subjects: 0
Study 12192254 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10518846 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.25 mg once daily
Number of subjects: 0
Study 10518846 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.5 mg once daily
Number of subjects: 0
Study 10518846 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 1.0 mg once daily
Number of subjects: 0
Study 10518846 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.25 mg twice daily
Number of subjects: 0
Study 10518846 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.5 mg twice daily
Number of subjects: 0
Study 10518846 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 1.0 mg twice daily
Number of subjects: 0
Study 10518846 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.25 mg once daily (study C)
Number of subjects: 0
Study 10518846 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.5 mg twice daily (study C)
Number of subjects: 0
Study 10518846 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 1.0 mg once daily (study C)
Number of subjects: 0
Study 8748720 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical terbutaline sulfate (1.0 mg)
Number of subjects: 12
Study 8748720 — intervention group
Group type: COMPARATOR
Intervention: Diluent (placebo)
Number of subjects: 12
Study 1976563 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 120
Study 1976563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 7004292 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol (25 mg tablets, four times daily for 4 weeks)
Number of subjects: 44
Study 7004292 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four times daily for 4 weeks)
Number of subjects: 44
Study 7004292 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 44
Study 7004292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 31514744 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (fixation) of medial malleolus fractures
Number of subjects: 154
Study 31514744 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment (non-fixation) of medial malleolus fractures
Number of subjects: 154
Study 31514744 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (fixation)
Number of subjects: 154
Study 31514744 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment (non-fixation)
Number of subjects: 154
Study 28990241 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically indicated replacement of peripheral intravenous catheters (PIVC)
Number of subjects: 1198
Study 28990241 — intervention group
Group type: COMPARATOR
Intervention: Routine replacement of peripheral intravenous catheters (PIVC) every 72-96 hours
Number of subjects: 1198
Study 25381876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 274
Study 25381876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 274
Study 25381876 — intervention group
Group type: COMPARATOR
Intervention: Placebo + low-dose metformin
Number of subjects: 274
Study 25381876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin groups
Number of subjects: 274
Study 24289915 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifitegrast ophthalmic solution 5.0%
Number of subjects: 588
Study 24289915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 23781653 — intervention group
Group type: EXPERIMENTAL
Intervention: Brahma‐muhurtha group (rising before 4:30 am)
Number of subjects: 54
Study 23781653 — intervention group
Group type: COMPARATOR
Intervention: Control group (waking just before 7 am)
Number of subjects: 54
Study 19741313 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (25 g/day for 7 days, then 5 g/day for 14 days)
Number of subjects: 20
Study 19741313 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 g/day glucose for 7 days, then 30 g/day glucose for 14 days)
Number of subjects: 20
Study 19741313 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 20
Study 17559754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER (100 mg, 200 mg, 300 mg, or 400 mg once daily)
Number of subjects: 1020
Study 17559754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1020
Study 17559754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER
Number of subjects: 1020
Study 11103755 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 8
Study 11103755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8726237 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin, s.c. 200 U/kg of body weight three times a week for 6 weeks
Number of subjects: 20
Study 8726237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1416575 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasound
Number of subjects: 385
Study 1416575 — intervention group
Group type: COMPARATOR
Intervention: Contrast venography
Number of subjects: 385
Study 2933205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg)
Number of subjects: 8
Study 2933205 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg)
Number of subjects: 8
Study 2933205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31221619 — intervention group
Group type: EXPERIMENTAL
Intervention: Epacadostat 100 mg orally twice daily plus pembrolizumab 200 mg intravenously every 3 weeks
Number of subjects: 706
Study 31221619 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pembrolizumab
Number of subjects: 706
Study 31221619 — intervention group
Group type: EXPERIMENTAL
Intervention: Epacadostat plus pembrolizumab
Number of subjects: 706
Study 30536984 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocacy program for girls
Number of subjects: 0
Study 28459508 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint electric stimulation (AES)
Number of subjects: 40
Study 28459508 — intervention group
Group type: COMPARATOR
Intervention: Regular nursing care (RNC)
Number of subjects: 40
Study 24130088 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous skeletal myoblast transplantation (ASM-Tx) - low dosage (400 million cells)
Number of subjects: 7
Study 24130088 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous skeletal myoblast transplantation (ASM-Tx) - high dosage (800 million cells)
Number of subjects: 7
Study 24130088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 24130088 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG) with ASM-Tx
Number of subjects: 7
Study 24130088 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 7